Startups channel feed – Endpoints News

Startups channel feed

Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics

Last month

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Last month

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

Last month

Immunology startup RayThera secures $110M in Series A raise

Last month

ADC startup DualityBio seeks Hong Kong IPO amid precarious market

Last month

Exclusive: Neurona bags $102M to treat epilepsy with cell therapy

Last month

Eli Lilly adds obesity startup knownwell to its direct-to-consumer service

Last month

Atsena gets Bain's support in $150M Series C to thwart blindness with gene therapy

2 months ago

RNA editing startup raises $155M to bring liver and lung disease therapy into clinic

2 months ago

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

2 months ago

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025

2 months ago

Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others

2 months ago

Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025

2 months ago

Galatea Bio gets $25M to map genetic diversity of 10 million people, help pharma create new medicines

2 months ago

Aurion CEO is out as Alcon takes majority stake in cell therapy startup

2 months ago

ElevateBio trims workforce by 17%

2 months ago

Lyndra Therapeutics to wind down amid funding hurdles for long-acting drug technology

2 months ago

Ophthalmology startup Character Biosciences gets $93M for genetics-based approach

2 months ago

Another immunology biotech emerges as Hillstar takes flight with $67M

2 months ago

Tempero Bio, led by ex-Novartis execs, gets $70M to reduce substance use disorders

2 months ago

Belgian biotech Augustine gets $85M for neuro and cardiometabolic pills

2 months ago

SV Health Investors nabs $250M to fund dementia-focused biotechs

2 months ago

Ascendis’ China joint venture, Visen Pharmaceuticals, prices $86M Hong Kong IPO

2 months ago

Flagship's Ampersand gets Eli Lilly's support in $65M Series B

2 months ago

First page Previous page 1 234 5 6 Next page Last page